{"id":"NCT00229970","sponsor":"Organon and Co","briefTitle":"MK0476 Study in Adult Patients With Acute Asthma (0476-322)","officialTitle":"MK0476 Phase II/III Placebo Controlled Double Blind Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2006-10","completion":"2007-06","firstPosted":"2005-09-30","resultsPosted":"2009-07-17","lastUpdate":"2022-02-02"},"enrollment":225,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":[]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"This study evaluates the efficacy and safety of MK0476 intravenous administration in adult patients with acute asthma.","primaryOutcome":{"measure":"The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1)","timeFrame":"baseline over the first 60 minutes","effectByArm":[{"arm":"Montelukast 7 mg","deltaMin":0.09,"sd":null},{"arm":"Montelukast 14 mg","deltaMin":0.17,"sd":null},{"arm":"Placebo","deltaMin":0.01,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.022"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22742205"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Nasopharyngitis","White blood cell count increased","Glucose urine present","Upper respiratory tract inflammation","Blood urine present"]}}